Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Interventions: ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 48
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more

Conditions: Healthy Volunteers
Interventions: itraconazole, rifampin, mitapivat sulfate; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophrenia
Interventions: rasagiline (Pharmacodynamics), Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland

Conditions: Pain
Interventions: ABT-712 Extended-release, Hydrocodone/Acetaminophen Immediate-release, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Austin, Texas • San Marcos, Texas • Salt Lake City, Utah

Conditions: Asthma, Obesity
Interventions: Mitoquinol, Placebo oral tablet; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Durham, North Carolina • Burlington, Vermont

Conditions: PreDiabetes, Aging
Interventions: Metformin, Placebo Oral Tablet; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 30 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
Interventions: Everolimus blinded oral capsules, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Opioid-use Disorder
Interventions: PCP brief advice, Video doctor, Telephone health coaching, Nurse Care Manager (NCM) intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Gulf War Illness
Interventions: Methyl-P plus GWI Nutrient Formula; Drug
Lead sponsor: K-PAX Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Covid19
Interventions: Famotidine 20 milligram tablet; Drug
Lead sponsor: drpykessupplements.com; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Fairfield, Connecticut

Conditions: Depressive Episodes, Bipolar I Depression
Interventions: SEP-4199 CR; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, Ingestible Event Marker (IEM); Drug · Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 12
States / cities: Cerritos, California • Garden Grove, California • Long Beach, California + 9 more

Conditions: Renal Transplant
Interventions: Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: San Francisco, California • Atlanta, Georgia

Conditions: Preeclampsia, Gestational Hypertension
Interventions: spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Alzheimer Disease
Interventions: Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Weight Gain
Interventions: lorcaserin, Intensive dietary counseling; Drug · Behavioral
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Resmetirom; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more

Conditions: Primary Generalized Epilepsy
Interventions: Cenobamate, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 43
States / cities: Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more

Conditions: Dyspepsia and Other Specified Disorders of Function of Stomach
Interventions: Amitriptyline, Escitalopram, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more

Conditions: Multiple Myeloma
Interventions: Siltuximab, Dexamethasone; Biological · Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Duarte, California • Norwalk, Connecticut • Indianapolis, Indiana + 6 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: Acute Pain
Interventions: XG005 tablet, Placebo tablet; Drug
Lead sponsor: Xgene Pharmaceutical Group; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • San Diego, California • Hialeah, Florida + 5 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: VX-814, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Sacramento, California • Denver, Colorado + 19 more

Search by objective public record fields.

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

MitoQ for the Treatment of Metabolic Dysfunction in Asthma

A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Subthreshold Opioid Use Disorder Prevention (STOP) Trial

Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness

Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

Alzheimer's Disease: Therapeutic Potential of Estrogen

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

Functional Dyspepsia Treatment Trial

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

XG005 for Pain Control in Subjects Undergoing Bunionectomy

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype